IHC results verify that the ESR1 level is lower in psoriatic and recurrent lesions than in normal skin (Fig. 8a, b), indicating the clinical responsibility of ESR1 deficiency in psoriasis pathology and that FeN4O2-SACs may ameliorate psoriasis and avoid relapse by restoring ESR1. This evidence concerns the gene ESR1 and psoriasis.